10 Mar Mechanisms Behind Persistent Infections

Biofilm: A Central Pathophysiologic Driver of Persistent and Recurrent Infections

Not all infections exist in the same biological state. While some acute infections are dominated by planktonic, rapidly dividing organisms that respond predictably to antimicrobial therapy, many chronic, recurrent, and device-associated infections are driven by bacteria organized within biofilms. Increasing evidence indicates that biofilm formation is not an exception but rather a dominant microbial survival strategy, fundamentally altering disease course, host response, and treatment efficacy.¹–³

Prevalence and Clinical Relevance of Biofilm

Biofilm involvement is estimated in up to 80% of chronic infections and 65–70% of healthcare-associated infections, including prosthetic joint infections (PJIs), endocarditis, osteomyelitis, diabetic foot ulcers, and catheter-associated bloodstream infections.¹,⁵,⁶ Rather than representing a rare or advanced phenomenon, biofilm formation reflects the default bacterial growth phenotype under physiologic conditions, particularly in the presence of foreign material or damaged tissue.³,⁴

Host and Environmental Conditions Favoring Biofilm Formation

Biofilm development occurs when bacteria are permitted to adhere, persist, and adapt within a permissive microenvironment.

Foreign Bodies and Medical Devices

Non-biologic surfaces and local tissue disruption provide an ideal substrate for bacterial adhesion. Initial attachment can occur within hours of bacterial seeding and rapidly progress to biofilm maturation.⁵,⁶ Once established, bacteria become physically and metabolically shielded from host immune mechanisms and antimicrobial exposure.

Host Factors

Advanced age, diabetes, impaired perfusion, immunosuppression, and prior antimicrobial exposure increase biofilm predisposition.⁷ Importantly, biofilm formation does not require immunodeficiency; even immunocompetent hosts can develop biofilm-mediated infections when bacterial inoculum, surface characteristics, and local conditions permit.³,⁹

Prosthetic Joint Infections as a Biofilm Paradigm

PJIs exemplify the clinical consequences of biofilm biology. Even low-level bacterial contamination at the time of hardware implantation can seed a prosthesis. Once biofilm forms, organisms transition to a protected sessile state characterized by reduced metabolic activity and altered gene expression, rendering eradication with antibiotics alone difficult.⁵,⁶

This pathophysiology explains why PJIs often present indolently, respond incompletely to prolonged antimicrobial therapy, and recur after apparent clinical resolution. In many cases, surgical debridement, component exchange, or hardware removal is required to definitively disrupt the biofilm and achieve cure.⁵,⁷  The initial choice of an antibiotic that demonstrates biofilm penetration and rapid bactericidal activity under the biofilm matrix is of the upmost importance to prevent these major complications and procedures from being necessary. 

Biofilm Development: From Attachment to Persistence

Biofilm formation follows a conserved, multistep process¹,³:

1. Initial adhesion of planktonic bacteria to tissue or biomaterial surfaces
2. During Maturation, the bacteria produce an extracellular matrix composed of polysaccharides, proteins, and extracellular DNA to protect itself. 
3. Persistence, marked by metabolic downregulation, phenotypic heterogeneity, changes in pH, quorum sensing through gene regulation. 

Within this structured community, bacteria communicate, exchange genetic material, and exhibit collective behaviors that promote long-term survival.²,⁴

Mechanisms of Antimicrobial Failure in Biofilm-Associated Infection

Biofilm-associated infections demonstrate treatment failure through multiple, overlapping mechanisms⁷,⁸,¹⁰:

• Antibiotic tolerance: Organisms embedded in biofilm may exhibit up to a 1,000-fold reduction in antimicrobial susceptibility despite preserved in vitro MICs
• Limited antimicrobial penetration through the biofilm matrix
• Dormant and persister cell populations that evade antibiotics targeting active cell division
• Immune evasion, as phagocytes and antibodies cannot effectively access or eradicate biofilm-embedded organisms

Consequently, antimicrobial therapy may suppress planktonic shedding without eliminating the underlying infection, leading to relapse upon discontinuation.²,¹⁰

Clinical Patterns Suggestive of Biofilm-Mediated Infection

Although direct visualization of biofilm is uncommon in routine practice, several clinical features should prompt suspicion⁷,⁹:

• Recurrent infection with the same pathogen
• Inadequate response to appropriately selected and dosed antimicrobials
• Relapse following prolonged treatment
• Infection involving prosthetic material or indwelling devices

Why Biofilm Awareness Is Increasingly Critical

As antimicrobial resistance continues to rise, many perceived “resistant” infections are, in reality, manifestations of biofilm-associated tolerance rather than classical genetic resistance.⁴,⁸ Effective management requires a shift to choosing initial antibiotics that are cidal against sessile bacteria, penetrate biofilm, and maintain rapid cidal activity under the biofilm matrix. Recognizing biofilm as a central driver of persistent infection is essential to improving outcomes, minimizing recurrence, and aligning treatment strategies with microbial biology.

References

1. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002; https://journals.asm.org/doi/10.1128/cmr.15.2.167-193.2002 
2. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999; https://www.science.org/doi/10.1126/science.284.5418.1318 
3. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol. 2004; https://www.nature.com/articles/nrmicro821 
4. Flemming HC, Wingender J, Szewzyk U, et al. Biofilms: an emergent form of bacterial life. Nat Rev Microbiol. 2016; https://www.nature.com/articles/nrmicro.2016.94 
5. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004; https://www.nejm.org/doi/abs/10.1056/NEJMra040181 
6. Arciola CR, Campoccia D, Montanaro L. Implant infections: adhesion, biofilm formation and immune evasion. Nat Rev Microbiol. 2018; https://www.nature.com/articles/s41579-018-0019-y 
7. Lebeaux D, Ghigo JM, Beloin C. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol Mol Biol Rev. 2014; https://journals.asm.org/doi/10.1128/mmbr.00013-14 
8. Stewart PS, William Costerton J. Antibiotic resistance of bacteria in biofilms. Lancet. 2001; https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(01)05321-1/abstract 
9. Bjarnsholt T. The role of bacterial biofilms in chronic infections. APMIS Suppl. 2013; https://onlinelibrary.wiley.com/doi/10.1111/apm.12099 
10. Del Pozo JL, Patel R. The challenge of treating biofilm-associated bacterial infections. Clin Pharmacol Ther. 2007; https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1038/sj.clpt.6100247 

WWW4300126